Clinical and Molecular Characteristics Associated with Survival in Advanced Melanoma Treated with Checkpoint Inhibitors

Table 3

Baseline characteristics of patient molecular characteristics.

	CheckMate 037 Larkin et al. 2017		CheckMate 066 Robert et al. 2015		CheckMate 067 Wolchok et al. 2017			CheckMate 069 Hodi et al. 2016		KEYNOTE-002 Ribas et al. 2015			KEYNOTE-006 Schachter et al. 2017
Phase	III		III		III			III		II			III
No. of Patients	405		418		945			142		540			834
Arms	Nivo	ICC	Nivo	Daca	Nivo+Ipi	Nivo	Ipi	Nivo+Ipi	Ipi	Pemb 1	Pemb 2	ICC	Pemb 1	Pemb 2	Ipi
BRAF Wild	NR	NR	202	204	212	218	215	NR	NR	136	141	138	177	178	170
BRAF Mutated	60	29	NR	NR	102	98	100	22	10	44	40	41	98	97	107
PDL1 Positive	134	67	74	74				24	11	NR	NR	NR	225	221	225
PDL1 Negative	NR	NR	136	134	123	117	113	NR	NR	NR	NR	NR	49	54	47
LDH≤ULN	NR	NR	120	125	199	197	194	70	36	99	105	107	194	175	178
LDH>ULN	139	46	79	74	114	112	115	24	1	77	73	68	81	98	91

Different expression levels are used to stratify, and we have not included data from this study with respect to PD-1 expression outcomes due to non-availability of similar comparison.
Daca = dacarbazine; ECOG = eastern cooperative oncology group; Ipi = ipilimumab; ICC= investigator choice chemotherapy; LDH = lactate dehydrogenase; NR = not reported. Nivo = nivolumab; Pemb1 = pembrolizumab administration every 2 weeks; Pemb2 = q3 administration every 3 weeks; PD= programmed cell death; ULN=upper level of normal. 1 = stratification based on age > 65 years and <65 years.